Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 10:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 49 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Mannkind Corporation Clear all
Terminated Phase 3 Interventional Results available

Clinical Trial Evaluating the Efficacy and Safety of Technosphere® Inhalation Insulin (TI) Inhalation Powder Using the Gen2 Inhaler

NCT01196104
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Technosphere® Insulin Inhalation Powder, Insulin Aspart, Insulin Glargine
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
29
States / cities
Mobile, Alabama • Fresno, California • Long Beach, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2014 · Synced Oct 6, 2026, 10:07 AM EDT
Withdrawn Not applicable Interventional

Single Site, Single Subject, Treatment IND With Mannkind Corporation's Technosphere Inhalation System

NCT01459133
View directory record Official record
Conditions
Diabetes
Interventions
Technosphere® Insulin Inhalation System
Drug
Lead sponsor
South Orange County Endocrinology
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Laguna Hills, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Oct 6, 2026, 10:07 AM EDT
Completed Phase 4 Interventional

INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes

NCT05904743
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Afrezza, insulin degludec, Rapid-acting Insulin Analog, Basal Insulin
Biological
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
19
States / cities
Loma Linda, California • Santa Barbara, California • Aurora, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2024 · Synced Oct 6, 2026, 10:07 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate Insulin in the Blood After Inhalation of a Dry Powder Insulin Formulation (Called Technosphere®/Insulin) in Non-diabetic Patients With & Without Chronic Obstructive Pulmonary Disease (COPD)

NCT01021891
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Technosphere®/Insulin
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 70 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 17, 2013 · Synced Oct 6, 2026, 10:07 AM EDT
Terminated No phase listed Observational

Pulmonary Function Substudy for Subjects Enrolled in Studies MKC-TI-161, MKC-TI-162 or MKC-TI-166

NCT01201928
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions
Comparator administered in parent trial, Technosphere Insulin Inhalation Powder
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
14
States / cities
Fresno, California • Long Beach, California • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2012 · Synced Oct 6, 2026, 10:07 AM EDT
Completed No phase listed Observational

Effects of URI on Diabetic Subjects Utilizing Technosphere Insulin After a Meal Challenge

NCT00642681
View directory record Official record
Conditions
Diabetes Mellitus, Upper Respiratory Infection
Interventions
Technosphere Insulin
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
15
States / cities
Tuscon, Arizona • Fresno, California • Huntington Beach, California + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2014 · Synced Oct 6, 2026, 10:07 AM EDT
Completed Phase 1 Interventional

Single Dose, Single Administration Study of Technosphere Inhalation Powder in Diabetic Subjects With Mild or Moderate Kidney Disease Compared to Diabetic Subjects With Normal Kidney Function

NCT00626249
View directory record Official record
Conditions
Mild Nephropathy, Moderate Nephropathy, Diabetes Mellitus
Interventions
Technosphere Inhalation Powder
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
3
States / cities
Minneapolis, Minnesota • Omaha, Nebraska • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 17, 2013 · Synced Oct 6, 2026, 10:07 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety of Inhaled Insulin With Type 1 and Type 2 Diabetes

NCT00308737
View directory record Official record
Conditions
Diabetes, Type 1, Diabetes, Type 2
Interventions
Technosphere® Insulin Inhalation Powder, Usual Care
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 70 Years
Enrollment
2,053 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
82
States / cities
Phoenix, Arizona • Tempe, Arizona • Tucson, Arizona + 64 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2014 · Synced Oct 6, 2026, 10:07 AM EDT
Completed Phase 3 Interventional Results available

Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period

NCT01445951
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Technosphere® Insulin with MedTone C Inhaler, Technosphere ®Insulin with Gen2 Inhaler, Insulin Aspart in combination with a basal insulin
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years and older
Enrollment
518 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
58
States / cities
Burlingame, California • Escondido, California • Huntington Beach, California + 50 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2014 · Synced Oct 6, 2026, 10:07 AM EDT
Not listed Phase 4 Interventional

A Study to Evaluate Time in Range in Type 2 Diabetics Using Afrezza® Plus Basal Insulin Compared to Multiple Daily Injections

NCT04125082
View directory record Official record
Conditions
Type 2 Diabetes Treated With Insulin
Interventions
Afrezza Inhalant Product
Drug
Lead sponsor
Diabetes and Glandular Disease Clinic
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 30, 2020 · Synced Oct 6, 2026, 10:07 AM EDT
Recruiting Not applicable Interventional

Effect of Inhaled Technosphere Insulin vs RAA Insulin on Exercise-Induced Hypoglycemia in Adults With T1D Using Automated Insulin Delivery

NCT06880835
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Control IQ + sleep or exercise activity with TI
Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
Louisville, Kentucky • Philadelphia, Pennsylvania • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 6, 2026, 10:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Determine if Technosphere® Inhalation Powder (FDKP) Causes ECG Changes (QTc) Following the Medication's Inhaled Administration.

NCT00721344
View directory record Official record
Conditions
Healthy Subjects
Interventions
Technosphere Inhalation Powder (FDKP), Moxifloxacin, Placebo
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jun 13, 2012 · Synced Oct 6, 2026, 10:07 AM EDT
Completed Phase 3 Interventional Results available

Comparison of Technosphere® Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus

NCT01451398
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Technosphere® Insulin, Technosphere Powder
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years and older
Enrollment
353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
50
States / cities
Anaheim, California • Huntington Beach, California • Laguna Hills, California + 41 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2014 · Synced Oct 6, 2026, 10:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics, Safety and Tolerability of Treprostinil Inhalation Powder in Healthy Normal Volunteers

NCT03464864
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Treprostinil Inhalation Powder
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 30, 2018 · Synced Oct 6, 2026, 10:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Determine How Long Insulin and FDKP (the Molecule That Forms Technosphere Particles) Stays in the Lungs of Healthy Individuals After Inhalation of Technosphere® Insulin (TI) Powder Using Bronchoalveolar Lavage (BAL)

NCT00757367
View directory record Official record
Conditions
Healthy Subjects
Interventions
TI Inhalation Powder
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 45 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 17, 2013 · Synced Oct 6, 2026, 10:07 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-up

NCT00309244
View directory record Official record
Conditions
Diabetes Type 2
Interventions
Technosphere® Insulin Inhalation Powder, 70% insulin aspart protamine suspension and 30% insulin aspart injection (rDNA origin)
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
677 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
80
States / cities
Mobile, Alabama • Tucson, Arizona • Chula Vista, California + 54 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2014 · Synced Oct 6, 2026, 10:07 AM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy of Technosphere® Insulin Inhalation Powder and Lantus® Compared to Humalog® and Lantus® Over 16-Weeks

NCT00700622
View directory record Official record
Conditions
Diabetes, Type 1
Interventions
Technosphere Insulin, Insulin glargine, Insulin lispro
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
20
States / cities
Huntington Beach, California • La Jolla, California • San Mateo, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2014 · Synced Oct 6, 2026, 10:07 AM EDT
Not listed Phase 4 Interventional

A Randomized Controlled Trial Evaluating One Drop | Premium With Afrezza vs. One Drop | Premium Alone

NCT03313960
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Afrezza plus One Drop | Premium, One Drop | Premium
Drug · Other
Lead sponsor
Informed Data Systems, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Oct 6, 2026, 10:07 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Prandial Inhalation of Technosphere/Insulin in Combination With Metformin or Technosphere/Insulin Alone Versus 2 Oral Anti-Diabetic Agents in Subjects With Type 2 Diabetes

NCT00332488
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Technosphere Insulin, Metformin & Secretagogues, Technosphere Insulin & Metformin
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
547 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
43
States / cities
Birmingham, Alabama • Phoenix, Arizona • Chula Vista, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2014 · Synced Oct 6, 2026, 10:07 AM EDT
Completed Phase 2 Interventional Results available

Afrezza Safety and Pharmacokinetics Study in Pediatric Patients

NCT02527265
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Afrezza
Biological
Lead sponsor
Mannkind Corporation
Industry
Eligibility
4 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
13
States / cities
Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2021 · Synced Oct 6, 2026, 10:07 AM EDT
Terminated Phase 3 Interventional

Inhaled Technosphere Insulin in Subjects With Diabetes Mellitus and Asthma

NCT00332826
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Asthma
Interventions
Technosphere Insulin
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
25
States / cities
Phoenix, Arizona • Tempe, Arizona • Tucson, Arizona + 19 more
Source: ClinicalTrials.gov public record
Updated May 4, 2012 · Synced Oct 6, 2026, 10:07 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy & Safety of Inhaled Insulin in Type 1 Diabetes

NCT00308308
View directory record Official record
Conditions
Diabetes, Type I
Interventions
Technosphere Insulin, Active comparator
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
589 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
61
States / cities
Mobile, Alabama • Chandler, Arizona • Chula Vista, California + 48 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2014 · Synced Oct 6, 2026, 10:07 AM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Stage IV Melanoma

NCT00023647
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
Synchrotope TA2M
Biological
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 10, 2012 · Synced Oct 6, 2026, 10:07 AM EDT
Completed Phase 1 Interventional

Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.

NCT00423254
View directory record Official record
Conditions
Ovarian, Melanoma, Renal, Prostate, Colorectal, Endometrial Carcinoma, Cervical Carcinoma, Testicular Cancer, Thyroid Cancer, Small Cell Lung Carcinoma, Mesothelioma, Breast Carcinoma, Esophageal Carcinoma, Gastric Cancer, Pancreatic Carcinoma, Neuroendocrine Cancer, Liver Cancer, Gallbladder Cancer, Biliary Tract Cancer, Anal Carcinoma, Bone Sarcomas, Soft Tissue Sarcomas, Carcinoma of Unknown Origin, Primary
Interventions
PSMA/PRAME
Biological
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
5
States / cities
Tuscon, Arizona • Washington D.C., District of Columbia • Tampa, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2010 · Synced Oct 6, 2026, 10:07 AM EDT